Geron Corporation - Common Stock – Bilanz (NASDAQ:GERN)

Financials

Gesamtvermögen 270.73 M226.03 M190.57 M394.08 M593.78 M570.54 M Gesamtverbindlichkeiten 59.78 M99.62 M110.58 M146.13 M313.46 M344.67 M Gesamtkapital 210.95 M126.42 M80 M247.95 M280.32 M225.87 M Gesamtverbindlichkeiten und Eigenkapital 270.73 M226.03 M190.57 M394.08 M593.78 M570.54 M Gesamtverschuldung 24.04 M49.83 M51.16 M81.94 M165.37 M119.55 M Nettoverschuldung 24.04 M49.83 M51.16 M81.94 M165.37 M41.99 M

Geron Corporation - Common Stock

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

GERN

Financials

Geron Corporation - Common Stock

Nachrichten

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates

Geron auf der Barclays Healthcare-Konferenz: Strategisches Wachstum und Zukunftspläne

Geron at Barclays Healthcare Conference: Strategic Growth and Future Plans

Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Geron at TD Cowen: Strategic Growth and Market Expansion

Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings (NASDAQ:GERN)

Geron Corporation (GERN) Q4 2025 Earnings Call Transcript

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron: EPS verfehlt Schätzungen um 0,02 $ - Umsatz schlechter als erwartet